Cytokinetics CYTK EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's EPS (diluted)?
- Cytokinetics (CYTK) reported EPS (diluted) of -$1.67 in Q1 2026.
- How has Cytokinetics's EPS (diluted) changed year-over-year?
- Cytokinetics's EPS (diluted) decreased by 22.8% year-over-year, from -$1.36 to -$1.67.
- What is the long-term trend for Cytokinetics's EPS (diluted)?
- Over 4 years (2021 to 2025), Cytokinetics's EPS (diluted) has grown at a 23.7% compound annual growth rate (CAGR), from -$2.79 to -$6.53.
- What does EPS (diluted) mean?
- The profit per share if all potential sources of new shares were converted into stock.
- How do you interpret EPS (diluted)?
- A higher value indicates better earnings performance, while a significant gap between basic and diluted EPS highlights potential shareholder dilution.
- How does EPS (diluted) compare across companies?
- Standard metric for public companies to account for potential dilution from employee stock plans and convertible instruments.